Company Encyclopedia
View More
name
R&G Pharma
301333.SZ
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services.
569.27 B
301333.SZMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking7/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.17%B
    • Profit Margin19.17%A
    • Gross Margin32.74%C
  • Growth ScoreC
    • Revenue YoY4.06%C
    • Net Profit YoY25.00%B
    • Total Assets YoY0.95%C
    • Net Assets YoY7.65%B
  • Cash ScoreC
    • Cash Flow Margin521.53%C
    • OCF YoY4.06%C
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreA
    • Gearing Ratio17.01%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    R&G Pharma: Abnormal fluctuations in stock trading

    R&G Pharma announced that the closing price increase deviation of the company's stock exceeded 30% cumulatively over three consecutive trading days on October 29, 2025, October 30, 2025, and October 31, 2025. There are no corrections or supplements needed for the information previously disclosed by the company, and there have been no significant changes in the company's operating conditions or internal and external operating environment recently. The company, its controlling shareholders, and actual controllers do not have any significant matters related to the company that should be disclosed but have not been disclosed

    Zhitong·
    SZ
    301333
    +4.47%
    Zhitong·
    SZ
    301333
    +4.47%

    The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine

    Zhitong·
    SZ
    301230
    +0.10%
    SZ
    300347
    +0.93%
    HK
    03347
    +1.68%
    Zhitong·
    SZ
    301230
    +0.10%
    SZ
    300347
    +0.93%
    HK
    03347
    +1.68%

    R&G Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 95.5668 million yuan, an increase of 13.21%

    According to the Zhitong Finance APP, R&G Pharma released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 607 million yuan, a year-on-year increase of 8.09%. The net profit attributable to shareholders of the listed company was 95.5668 million yuan, a year-on-year increase of 13.21%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 81.3334 million yuan, a year-on-year increase of 22.47%. The basic earnings per share were 1 yuan

    Zhitong·
    SZ
    301333
    +4.47%
    Zhitong·
    SZ
    301333
    +4.47%

    R&G Pharma plans to launch an employee stock ownership plan in 2025 with a total funding not exceeding 15 million yuan

    R&G Pharma plans to implement an employee stock ownership plan in 2025, with a total funding amount not exceeding 15 million yuan. The funding sources include the company's reward fund and other legal means. The planned stock scale is not more than 385,800 shares, with a repurchase price of 38.88 yuan per share, and a duration of 36 months

    Zhitong·
    SZ
    301333
    +4.47%
    Zhitong·
    SZ
    301333
    +4.47%

    R&G Pharma: Net profit of 61.1161 million yuan in the first half of 2025, a year-on-year increase of 4.45%

    R&G Pharma announced that in the first half of 2025, operating revenue will be 380 million yuan, a year-on-year increase of 0.18%. Net profit will be 61.1161 million yuan, a year-on-year increase of 4.45%

    Zhitong·
    SZ
    301333
    +4.47%
    Zhitong·
    SZ
    301333
    +4.47%
    © 2025 Longbridge｜Disclaimer